Volume 28, Issue 152, October 2024

Change in HbA1c in Adults with type 2 diabetes mellitus using dapagliflozin 10mg and related side effects in King Abdulaziz Medical City, Saudi Arabia

Khalid G Alharbi^1♦, Hamad Alkanhal¹, Eman G Alharbi², Bader Altulaihi³

¹Resident at Family Medicine Department, King Abdulaziz Medical City Riyadh, Riyadh, Kingdom of Saudi Arabia
²Diabetes Clinical Fellow at university Diabetes Center, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia
³Consultant, Family Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia

^♦Corresponding Author
Resident at Family Medicine Department, King Abdulaziz Medical City Riyadh, Riyadh, Kingdom of Saudi Arabia

ABSTRACT

Diabetes is a common disease characterized by impaired glycemic control in the body. High blood glucose readings are any fasting blood glucose more than or equal to 126 mg/dl, random blood glucose more than or equal to 200 mg/dl, or A1c level greater than or equal to 6.5%. We used a retrospective, chart review study design to collect the A1c readings in patients using Dapagliflozin 10mg. The total sample size was 57 participants. Even though SGLT-2 inhibitors weakly reduce HbA1c, we have found in our study that Dapagliflozin has significantly decreased A1c in addition to a reduction in weight especially among females. Reported side effects were minimal with the majority having no side effects. However, 4 participants reported urinary side effects that were subsequently treated and improved.

Keywords: Type 2 diabetes mellitus, hba1c, semaglutide, dapagliflozin, sglt-2 inhibitors

Medical Science, 2024, 28, e131ms3441

PDF

DOI: https://doi.org/10.54905/disssi.v28i152.e131ms3441

Published: 27 October 2024